Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while GraniteShares 2x Long COIN Daily ETF trades at $4.11. Which is the better fit depends on your goals.
| ALNY | CONL | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $48.70 |
52-Week Low | $205.48 | $3.93 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.11, up 0.49% on the day but reflecting a bearish technical signal with moving averages indicating strong selling pressure. The ETF has experienced significant volatility and value erosion, with news highlighting a 67% year-to-date loss as of June 2026 due to the daily-reset leverage structure amplifying Coinbase's price swings. Key financial ratios are not applicable as this is a leveraged ETF tracking another security.
Outlook remains highly speculative and risky due to the ETF's daily leverage, which can lead to rapid losses in volatile markets. Investment opportunity is limited to short-term traders betting on Coinbase rallies, but risks include volatility decay, tracking error, and dependence on Coinbase performance. Long-term holding is discouraged by the structure's inherent erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
